ABSTRACT The in vivo incorporation of [4,5-3H]leucine and [2-3H]mannose into the lysine-Sepharose affinity chromatography-resolvable carbohydrate variants of rat and rabbit plasminogen has been studied in the absence and presence of tunicamycin (TM). When rabbits and rats were exposed to 0.5 mg of TM per kg of body weight for 30 min and 2 hr, respectively, followed by a single pulse of [4,5-3H]leucine for 2 hr, no radiolabel was found in rat or rabbit variant 1 plasminogen, whereas [4,5-3H] Plasminogen, the plasma protein zymogen of the fibrinolytic enzyme plasmin, can be resolved into two major variants by affinity chromatography on lysine-Sepharose (1). The major, if not the only, chemical difference between these variants is their relative extent of glycosylation (2, 3). In the human system, affinity chromatography variant 1 possesses two sites of glycosylation, at amino acid residues Asn-288 and Thr-345 (4-6). On the other hand, affinity chromatography variant 2 contains only the Thr-345-based carbohydrate (4-6). The carbohydrate composition ofthe rabbit plasminogen affinity chromatography variants strongly suggests that a similar situation exists in this species (2, 3) . No other chemical differences in the major forms of plasminogen have been thus far observed. Both plasminogen variants have been clearly shown to be synthesized in primary cultures of rat parenchymal hepatocytes (7) .
Plasminogen, the plasma protein zymogen of the fibrinolytic enzyme plasmin, can be resolved into two major variants by affinity chromatography on lysine-Sepharose (1). The major, if not the only, chemical difference between these variants is their relative extent of glycosylation (2, 3) . In the human system, affinity chromatography variant 1 possesses two sites of glycosylation, at amino acid residues Asn-288 and Thr-345 (4) (5) (6) . On the other hand, affinity chromatography variant 2 contains only the Thr-345-based carbohydrate (4) (5) (6) . The carbohydrate composition ofthe rabbit plasminogen affinity chromatography variants strongly suggests that a similar situation exists in this species (2, 3) . No other chemical differences in the major forms of plasminogen have been thus far observed. Both plasminogen variants have been clearly shown to be synthesized in primary cultures of rat parenchymal hepatocytes (7) .
Because the ligand utilized for the affinity chromatography resolution ofnative plasminogen induces a large conformational alteration in the protein (8) and has been shown to be important in several of its functional properties, including its activation rate (9) and binding to fibrin (10) , we have attempted in this study to relate the chemical difference, glycosylation, in the plasminogen variants to their functional difference, in binding to lysine-Sepharose. Because tunicamycin (TM) blocks the Nglycosylation ofproteins (11, 12) , we felt that an excellent in vivo method was available to allow us to chemically convert affinity variant 1 plasminogen into affinity variant 2. The success of this attempt, as well as its resulting effect on plasminogen functional properties, is the subject of this communication.
MATERIALS AND METHODS
Materials. TM was purchased from Calbiochem. Approximately 5.5 mg was dissolved in 10 ml of0.15 M NaCl (pH 7.0). A few drops of a solution of 10 mM NaOH were added in order to achieve a pH ofapproximately 10 Lysine-Sepharose was prepared as described (13) . The gel was packed into a 1 x 15 cm column and equilibrated with a buffer consisting of 0.3 M sodium phosphate, pH 8.0. Scintillation fluid contained 4 g of2,5-diphenyloxazole (Packard) and 0.1 g of1,4-bis[2-(4-methyl-5-phenyloxazolyl)]benzene (Packard) per liter of toluene. One volume of Triton X-100 (Rohm and Haas, Philadelphia) was added to 2 vol ofscintillation fluid. All scintillation counting was performed with a Beckman DPM-100 counter.
The rats used in these experiments were of the Wistar strain and New Zealand White rabbits were purchased from a local breeder.
Appearance of [4,5-3H] Leucine in Plasminogen and Plasma Proteins. These experiments were performed in both rats and rabbits. In the control animals, a quantity of 0.5 ml (0.5 mCi) of [4,5-3H ]leucine for rats (ca. 300-400 g) or 2.0 ml (2.0 mCi) for rabbits (ca. 2-3 kg) was injected into the hind leg muscles. After 2 hr, the rats were rapidly decapitated and bled into a solution containing 1 The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact.
or TM-treated animals was passed over a 1.0 X 15.0 cm column oflysine-Sepharose at room temperature (14) . After application of the relevant plasma, the column was washed with 300 ml of 0.3 M sodium phosphate (pH 8.0) followed by 50 ml of 0.1 M sodium phosphate (pH 8.0). In order to elute the plasminogen variants, a gradient consisting of 50 ml of 0.1 M sodium phosphate (pH 8.0) as the starting buffer and 50 ml of0.1 M sodium phosphate/0. 018 M E-aminocaproic acid (EACA) (pH 8.0) as the limit buffer was employed. The column was developed at 30 ml/hr and approximately 1.0-ml fractions were collected. For each fraction, the absorbance at 230 nm was determined. The level of [4,5-3H] leucine incorporated into each plasminogen variant was assayed by mixing 0.35 ml ofeach fraction with 0.65 ml of H20 and adding to this 10 ml of scintillation fluid.
For measurement of [4,5-3H] leucine incorporation into total trichloroacetic acid-precipitible rat and rabbit plasma protein, 0.2 ml ofplasma was mixed with 3 ml of 10% trichloroacetic acid and the suspension thus obtained was subjected to low-speed centrifugation. The precipitate was washed five times in the same manner. After the final wash, the precipitate was dissolved in 2 ml of 0.5 M NaOH. An aliquot (0.2 ml) of this solution was then mixed with 0.8 ml of H20 and to this was added 10 ml of scintillation cocktail.
Incorporation of [2-3H] Mannose into Plasminogen and Plasma Proteins. These experiments were performed as above, with a few important exceptions. First, much larger quantities of mannose were injected due to the low level of mannose in plasminogen, compared to leucine. Therefore, injections of 1.0 mCi of [2-3H] mannose into rat and 4.0 mCi into rabbit hind leg muscles were utilized in normal and TM-treated animals. Next, individual column fractions ofplasminogen could not be assayed Proc. Natl. Acad. Sci. USA 78 (1981) 6837 for radiolabel and only the pooled peaks were assayed. In order to accomplish this, pooled plasminogen variants 1 and 2 from the lysine-Sepharose columns were extensively dialyzed against H20 and lyophilized. The proteins were then dissolved in 1.5 ml of 50 mM Tris.HCl/100 mM NaCl/10 mM EACA (pH 7.4). To this solution was added 15 ml of Bio-Fluor (New England Nuclear), in order to enhance counting efficiencies, and radioactivity levels were determined as above.
Incorporation of [2-3H]mannose into acid-precipitated plasma proteins was measured as described above. RESULTS Fig. 1 illustrates the elution of the two affinity chromatography variants of rat plasminogen from the plasma of single rats that was taken approximately 2 hr after intramuscular injections of [4,5-3H] leucine, in animals not pretreated and pretreated with tunicamycin. In rats not treated with TM, each plasminogen variant contains radiolabeled leucine. When animals were pretreated with TM, essentially no radiolabeled leucine was incorporated into rat plasminogen variant 1, whereas incorporation into rat plasminogen variant 2 did indeed occur. Fig. 2 shows that virtually identical results were obtained when rabbits are used.
Each plasminogen fraction was pooled and the specific radioactivity of the plasminogen variants was determined. The results are summarized in Table 1 proximately 1.5-2.0 X the rate for variant 1, a conclusion that verifies our previously reported results (14, 15) . On the other hand, when the animals were pretreated with TM, the data of Table 1 show that virtually no radiolabel appeared in rat or rabbit plasminogen variant 1, but it did appear in rabbit variant 2, the latter at the same rate as in rabbit variant 2 in the absence of TM. In the case of rat variant 2, the rate of [4,5- Incorporation of [4,5-3H] leucine into the trichloroacetic acidprecipitable plasma proteins was also determined. For rat plasma, this amino acid was incorporated to the extent of 1.32 X 10' cpm/ml of plasma proteins (absence of TM) and 2.7 x 105 cpm/ml ofplasma proteins (presence ofTM) 2 hr after [4,5-3H] leucine injection. This indicated that the particular dosage schedule of TM led to depression of de novo synthesis or secretion ofgeneral plasma proteins. In the case ofrabbit plasma, the incorporation was 1.3 x 105 cpm/ml of plasma proteins in the absence or presence of TM, again 2 hr after injection of amino acid. This demonstrates that general plasma protein secretion or de novo synthesis may not have been grossly affected under these conditions. Table 2 shows the appearance of [2-3H] (4) . One form is glycosylated at Asn-288 and Thr-345 and the other is glycosylated only at Thr-345. The existence ofthese same variants in rat and rabbit plasma suggests a similar occurrence here, which is supported by the carbohydrate compositions of each isolated form (2, 3) . This type of diversity in carbohydrate of the same protein is rare; the more common modes of variation involve microheterogeneity in complex and hybrid-type oligosaccharides. One example ofthe latter is seen in the two hybrid types ofbovine rhodopsin, in which only partial addition of mannose and N-acetylglucosamine terminal groups occurs (16) .
From the results reported herein, we feel that the additional site of asparagine-linked glycosylation on affinity variant 1 of plasminogen is responsible for the EACA binding differences between the two forms, because blockage of this glycosylation step, by TM, serves to eliminate this functional variation. It can be argued that plasminogen variant 1 is not secreted in the presence ofTM, thus complicating the interpretation of Figs. 1 and  2 ; however, this is not a likely interpretation because plasminogen variant 2, which also lacks asparagine-linked oligosaccharide residues, and is synthesized at the same site as variant 1 (7) , is indeed secreted in the presence of TM.
The data presented in this manuscript serve to extend the question as to the biological function, if any, of the N-linked oligosaccharide of plasminogen variant 1, a topic that has been widely discussed for many glycoproteins. The necessity for Nglycosylation for plasminogen secretion to occur is unlikely, as argued above. Further, because the human plasminogen sequence contains an arginine residue at position 289, which is the carboxy-proximal residue of the oligosaccharide acceptor, Asn-288 (5, 17) , the presence of the carbohydrate may serve to protect this region from cleavage by trypsin-like proteases. In this manner glycosylation may serve to preserve the structural integrity of the molecule-an observation noted for another plasma glycoprotein, fibronectin (18, 19) . In addition, the strength and structural orientation of the plasminogen variants 1 and 2 in binding to fibrin may be affected by carbohydrate in a parallel manner to their differential binding to lysineSepharose.
The suggestion has been made that the low concentration of dolichol phosphate in the cell may be the rate-limiting factor for protein glycosylation (20) . The added metabolic steps required to trim and process the plasminogen variant 1 oligosaccharide may explain why variant 1 appears in the plasma at half the rate, compared to variant 2. The half-life of rabbit and rat plasminogen is roughly 12 hr (14) , indicating rapid turnover, and this, coupled with the rate-limiting dolichol phosphate concentration may, in part, serve to explain why the total plasminogen pool is incompletely N-glycosylated.
Because of the ease of isolation of the plasminogen variants from whole plasma, an in vivo system for studying the effects of TM on this protein has been shown to be quite effective. These results with TM in a whole animal study more generally suggest that the other plasma glycoproteins, as well, may be -obtainable in their nonglycosylated forms.
